The Life Sciences team advised K36 Therapeutics on its $70 million Series B financing.
K36 Therapeutics is a privately held clinical-stage biotech company developing KTX-1001, an investigational small molecule methyltransferase inhibitor of multiple myeloma SET (MMSET) domain.
The funds will support the ongoing Phase 1 study of KTX-1001, planned clinical studies of KTX-1001 in combination with existing standard-of-care agents in multiple myeloma, and the expansion of KTX-1001 into additional hematological and solid tumor indications. KTX-1001 is a novel, first-in-class, potent, and selective catalytic inhibitor of the H3K36 methyltransferase MMSET. It is an orally administered small molecule being developed initially for treating relapsed and refractory multiple myeloma, focusing on patients with the genetic translocation t(4;14).
The Goodwin team was led by Kingsley Taft, and included Joseph Jung Hyuk Yim, Samantha Jandl, Aniko Bouley (Corporate) and Scott Zilora and Joseph Coughlin (Modeling) with invaluable support from Amy Josselyn and Gozde Guckaya (Global Trades).
For more details, read the press release and articles in Endpoints News.